Detailed information
Notice
The information is provided in the language in which it was submitted by the researcher.
- Project title:
- Advanced immunotherapeutic oncolytic reovirus combination therapy for breast cancer.
- Principal investigator(s):
- Shmulevitz, Maya
- Co-investigator(s):
- N/A
- Supervisors:
- N/A
- Institution paid:
- University of Alberta
- Research institution:
- University of Alberta
- Department:
- Medical Microbiology and Immunology
- Program:
- Project Grant
- Competition (year/month):
- 202109
- Assigned peer review committee:
- Virology & Viral Pathogenesis
- Primary institute:
- Infection and Immunity
- Primary theme:
- Biomedical
- Term (yrs/mths):
- 5 yrs 0 mth
- CIHR contribution:
- Contributors:
- Amount:
- $902,700
- Equipment:
- $0
- External funding partner(s):
- Partner Name:
- N/A
- Amount:
- N/A
- Equipment:
- N/A
- External applicant partner(s):
- Partner Name:
- N/A
- Amount:
- N/A
- Equipment:
- N/A
- External in-kind partner(s):
- Partner Name:
- N/A
- Amount:
- N/A
- Equipment:
- N/A
- Keywords:
- Breast Cancer; Oncolytic Virus; Tumor Immunology; Virus Antigenicity; Virus-Based Therapies
- Abstract/Summary:
- Viruses like reovirus are natural cell killers and immune stimulators, thus offering a unique approach to directly kill tumor cells and stimulate anti-tumor immunity. Our project will advance reovirus-based therapy of breast cancer by using combinations of innovations generated by our lab and others. We will also reveal important changes in the immune system that correspond with improved breast cancer outcomes, and identify limitations of reovirus therapy that need to be addressed by future advancements. Our project will also reveal the impact of host anti-reovirus antibodies on reovirus therapies and exploit novel reoviruses to overcome antibody-based inactivation of reovirus in tumors.
- Version:
- 20250311.1